Front Row Advisors’s Amedisys AMED Stock Holding History

Front Row Advisors’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-27	Closed	-$2.48K	–	514
2024 Q2	$2.48K	Hold	27	–	–	﹤0.01%	831
2024 Q1	$2.49K	Buy	+27	New	+$2.53K	﹤0.01%	822
2023 Q4	–	Sell	-27	Closed	-$2.52K	–	487
2023 Q3	$2.52K	Hold	27	–	–	﹤0.01%	786
2023 Q2	$2K	Hold	27	–	–	﹤0.01%	791
2023 Q1	$2K	Hold	27	–	–	﹤0.01%	806
2022 Q4	$2K	Hold	27	–	–	﹤0.01%	770
2022 Q3	$3K	Hold	27	–	–	﹤0.01%	736
2022 Q2	$3K	Hold	27	–	–	﹤0.01%	744
2022 Q1	$5K	Hold	27	–	–	﹤0.01%	704
2021 Q4	$4K	Hold	27	–	–	﹤0.01%	775
2021 Q3	$4K	Hold	27	–	–	﹤0.01%	763
2021 Q2	$5K	Hold	27	–	–	﹤0.01%	727
2021 Q1	$7K	Hold	27	–	–	﹤0.01%	620
2020 Q4	$8K	Hold	27	–	–	﹤0.01%	559
2020 Q3	$6K	Hold	27	–	–	﹤0.01%	626
2020 Q2	$5K	Hold	27	–	–	﹤0.01%	614
2020 Q1	$5K	Sell	27 -10	-27%	-$1.78K	﹤0.01%	604
2019 Q4	$6K	Hold	37	–	–	﹤0.01%	565
2019 Q3	$5K	Hold	37	–	–	﹤0.01%	578
2019 Q2	$4K	Hold	37	–	–	﹤0.01%	624
2019 Q1	$5K	Hold	37	–	–	﹤0.01%	567
2018 Q4	$4K	Hold	37	–	–	﹤0.01%	575
2018 Q3	$4	Hold	37	–	–	﹤0.01%	590
2018 Q2	$3	Hold	37	–	–	﹤0.01%	725
2018 Q1	$2K	Hold	37	–	–	﹤0.01%	764
2017 Q4	$2K	Buy	+37	New	+$1.95K	﹤0.01%	662

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Front Row Advisors's AMED Position: Q3 2024 in Review

Front Row Advisors sold out of Amedisys (AMED) in Q3 2024, closing a stake of 27 shares — an estimated $2.48K sold.

Front Row Advisors first reported a position in AMED in Q4 2017 and held it in 26 quarters. The position peaked at $8K in Q4 2020. 285 funds tracked by Wall St. Rank hold AMED as of Q3 2024.

Front Row Advisors reported no remaining Amedisys position as of Q3 2024 after selling out during the quarter.
Front Row Advisors sold 27 Amedisys shares in Q3 2024, an estimated $2.48K.
Front Row Advisors first reported a position in Amedisys in Q4 2017 and held it in 26 quarters.
Front Row Advisors's Amedisys position peaked at $8K in Q4 2020.
285 funds tracked by Wall St. Rank held Amedisys as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.